TMO Stock Overview
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
The demand for personalized medicine will keep Thermo Fisher Scientific thriving
Stellar Spectrometer Launch And AI Adoption Will Boost Future Operational Efficiency
Thermo Fisher Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$521.50 |
| 52 Week High | US$627.88 |
| 52 Week Low | US$493.30 |
| Beta | 0.79 |
| 1 Month Change | -1.95% |
| 3 Month Change | 1.03% |
| 1 Year Change | -10.51% |
| 3 Year Change | -11.21% |
| 5 Year Change | 84.91% |
| Change since IPO | 16,515.97% |
Recent News & Updates
Recent updates
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences
Mar 07Earnings Preview: Thermo Fisher Is Facing Way Too Many Headwinds
Jan 29Biologicals Is The Future In Thermo Fisher: Buy Rating
Jan 22An Intrinsic Calculation For Thermo Fisher Scientific Inc. (NYSE:TMO) Suggests It's 31% Undervalued
Jan 18
Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 31Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Not Quite Adding Up
Dec 13Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic
Dec 10Thermo Fisher: M&A And Innovation To Drive Sales Growth
Dec 04Thermo Fisher Scientific: Near The Bottom And Attractively Valued
Nov 14Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
Oct 23Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Oct 04These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24Thermo Fisher Scientific: Too Hot To Handle
Apr 15Shareholder Returns
| TMO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.4% | 0.4% | 1.7% |
| 1Y | -10.5% | -18.8% | 10.0% |
Return vs Industry: TMO exceeded the US Life Sciences industry which returned -18.8% over the past year.
Return vs Market: TMO underperformed the US Market which returned 10% over the past year.
Price Volatility
| TMO volatility | |
|---|---|
| TMO Average Weekly Movement | 3.6% |
| Life Sciences Industry Average Movement | 9.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: TMO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TMO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 125,000 | Marc Casper | www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Thermo Fisher Scientific Inc. Fundamentals Summary
| TMO fundamental statistics | |
|---|---|
| Market cap | US$196.01b |
| Earnings (TTM) | US$6.34b |
| Revenue (TTM) | US$42.88b |
31.1x
P/E Ratio4.6x
P/S RatioIs TMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMO income statement (TTM) | |
|---|---|
| Revenue | US$42.88b |
| Cost of Revenue | US$25.20b |
| Gross Profit | US$17.68b |
| Other Expenses | US$11.35b |
| Earnings | US$6.34b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.79 |
| Gross Margin | 41.23% |
| Net Profit Margin | 14.77% |
| Debt/Equity Ratio | 62.7% |
How did TMO perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield9%
Payout RatioDoes TMO pay a reliable dividends?
See TMO dividend history and benchmarks| Thermo Fisher Scientific dividend dates | |
|---|---|
| Ex Dividend Date | Mar 14 2025 |
| Dividend Pay Date | Apr 15 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 27 days |
Does TMO pay a reliable dividends?
See TMO dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 21:54 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Thermo Fisher Scientific Inc. is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |